Insomnia and its association with quality of life in women with ovarian cancer
Tanya L. Ross(QIMR Berghofer Medical Research Institute), Vanessa L. Beesley(QIMR Berghofer Medical Research Institute), Anna DeFazio(The University of Sydney), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Christina M. Nagle(The University of Queensland), Peter Grant(The University of Melbourne), Merran Williams, Michael Friedländer(Prince of Wales Hospital)
Cited by 33
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k